Challenge

A pharma company conducted a risk assessment for potential natural disasters and shipping constraints in their supply chain.

As a result of such assessment, the company approached Bend Bioscience to strengthen the company’s supply chain for its immediate-release tablet product. The company made the decision to move manufacturing of its product into the U.S., its biggest market, to reduce supply and revenue risks.

 

Objectives

Our Georgia manufacturing site was selected by the pharma company after a lengthy evaluation of several possible U.S. CDMOs. Once selected, we assembled a high-functioning team to transfer the company’s analytical and manufacturing to our Georgia manufacturing facility and to support the company’s